Revised code to increase investor confidence: promote it on your website
Biotechnology companies are urged to display their adherence to the ‘Code of Best Practice for Reporting by Life Science Companies’ on the company website - either on the front page or on the investor relations landing page.
The code has recently been revised and updated in consultation with the ASX and industry experts. An online endorsement ‘button’ for the use of companies that have implemented the code is available free of charge to indicate to investors that the company seeks to disclose according to best practice in accordance with the code, thus giving investors assurance in the life science business.

The code aims to support the directors and management of Australian ASX-listed life science companies to adopt international best practice in reporting events to investors. It also seeks to provide investors with a level of confidence through providing guidance on disclosure and appropriate reporting, as well as educational support regarding clinical trials and other matters.
More information can be found at www.ausbiotech.org/biotechboards.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
